This is a Phase 2, single-site, randomized, double-blind, placebo-controlled,
proof-of-concept (POC) study involving 6 weeks of MAP4343 in conjunction with 6 weeks of
manual-guided counseling, with 2 follow-up visits at 1 week and 1 month post-treatment.
Phase:
Phase 2
Details
Lead Sponsor:
The Scripps Research Institute
Collaborators:
Mapreg National Institute on Alcohol Abuse and Alcoholism (NIAAA)